Dr. Kyle McMorries at the team at Nacodoches Women's Center (NWC) share their thoughts on how Nuvo's remote NST solution is helping their practice and patients. Here are a few quotes:

“We’re able to decrease latency and increase throughput because NST’s are out of the office in a more comfortable place for the patient.” - Dr. Kyle McMorries

“More than anything, Nuvo gives me peace of mind.” - NWC patient using Nuvo

"I can't imagine our practice without using INVU." - Alisa King, BSN, RN, CLC

Check out the full video here:

Transcript:

Dr. McMorries: We started to offer Nuvo to our patients in response to a lot of changes that were occurring geographically. We're in rural East Texas and several of the outlying hospitals that we're offering maternity services have shut down and for a lot of our patients that means they're 45 minutes to an hour and a half from the nearest delivering facility or maternal prenatal care center. 

Patient (Chelsea): I would have had to move to Nacogoches. I had not experienced pregnancy and anxiety ever before, like I just you got the blue lines and you're excited and that was it like you had a baby like you didn't have to worry about anything bad happening. So after we lost her I was very very very worried about him and just constantly worried that something was going to go wrong and so the minute that they did let me have the (Nuvo) monitor it helped so much.

Patient (Felicia): Really more than anything it gives me a piece of mind being a high-risk pregnancy. Kyle had talked to me about how often I would have to monitor the baby and so working full-time, Nuvo was an option where I could use it at work or at home and I wouldn't have to drive. I live an hour away from the clinic so I wouldn't have to drive an hour to be able to monitor the baby as much. 

Nurse (Alisa): It was very very nice for me personally as the nurse that was doing all of the NST’s. It allowed me to monitor eight patients at one time in a one hour period as opposed to having eight patients sprinkled all throughout the day and then that was that was the day and it would take up exam rooms and so for me personally it's been great. It's been good for the provider too because then that's not an exam room that's being used.

Dr. McMorries: The recommendation for Nuvo to other practices is two thumbs up and I would say as an office it's been extremely positive because of decreasing the latency of our rooms we're basically able to increase our throughput because of that (NST’s) being out of the office into a more comfortable place for the patient, so overall it's a very positive experience we very much recommend it. 

Nurse (Alisa): Honestly, I can't say enough positive things about it. We're going on 2 years and I can't imagine our practice without using INVU.

‍

Nacogdoches Women's Center has fully integrated Nuvo into their practice and conducts nearly all of their NST's remotely using the INVU by Nuvo platform. This has improved staff efficiency and patient satisfaction, while cost-effectively increasing revenue to their practice.

"The biggest impact I've seen is that we freed up space in the office so that we're able to see patients that have problems or more acute issues." - Dr. Kyle McMorries

Check out the full video here:

‍

Transcript: 

Dr. Kyle McMorries: Nuvo has had a positive financial impact on our practice in a couple of ways. The main benefit we've seen is by keeping patients at home, keeping patients happy and being able to reach patients who are particularly high-risk in areas that are further away from our office. We've seen upticks in the number of patients that we've been able to attract from those different markets. The biggest impact I've seen is that we freed up space in the office so that we're able to see patients that have problems or more acute issues.

‍

Nacogdoches Women's Center has fully integrated Nuvo into their practice and conducts nearly all of their NST's remotely using the INVU by Nuvo platform. This has improved staff efficiency and patient satisfaction, while cost-effectively increasing revenue to their practice.

"I have to admit as a labor and delivery nurse I was a little skeptical at first because I thought “how is a patient going to monitor themselves at home”, but I have been shocked and amazed at how amazing it has worked, even better than our NST machine in the office when we have to use it." - Alisa King, OB nurse at Nacogdoches Women's Center.

Check out the full video here: 

We are pleased to share this short testimonial video from Deb Henretta, C-suite level executive and former head of Proctor & Gamble's global baby care business, sharing her perspective on the value Nuvo brings to patients and pregnancy care.

Nuvo gives patients the ability to attend NST appointments from wherever they need to be - at home, at work, or anywhere else. NWC patient, Felicia, shares her experience as a patient using Nuvo:

"My experience with Nuvo has been super easy so it's been very convenient for me to use it at work." - Felicia, NWC patient using Nuvo

"It's a great patient pleaser!" - Dr. Kyle McMorries

Check out the full video here: 

Transcript:

Patient (Felicia): My experience with Nuvo has been super easy so it's been very convenient for me to use it at work. I just shut my office door get it hooked up and then I can you know cover my belly back up and I can sit at my computer and still do all of my paperwork and stuff and even have meetings and things and people never even know that I'm monitoring.

Dr. Kyle McMorries: It's a great patient pleaser! Every patient we have on it loves the fact that they're not having to miss work, they're not having to drive in, they're not having to go through parking, checkin, and all the processes. Overall it's a very positive experience and we very much recommend it.

‍

Following Nuvo’s NASDAQ Listing, Addition of Machado Brings StrongHealth and Impact Experience to Remote Pregnancy Monitoring Pioneer

TELAVIV, Israel – May 9, 2024 – Holdco Nuvo Group D.G Ltd (NASDAQ: NUVO)(“Nuvo”), a pioneer in remote pregnancy monitoring, today announced the expansion of its board of directors with the addition of Adriana Machado, who will help guide Nuvo’s mission of addressing health disparities and social determinants of care through its advanced pregnancy monitoring technology.

“We are delighted to welcome Adriana to Nuvo’s board,” said Rice Powell, CEO of Nuvo. “She will provide a substantial health innovation perspective and female leadership that supports our mission. Adriana is also a true advocate for transformation and health equity, and we look forward to working with her to expand our efforts and market impact.”

Machado brings three decades of experience in business leadership, strategic planning and international relations. A celebrated business leader in Latin America, she was the first female CEO of GE Brazil, and is Founder of the Briyah Institute, aBenefit Corporation (B Corp) that ignites leaders to transform organizations by applying systems thinking to business. Ms. Machado holds board positions with various health and civil society organizations and, in 2013, was recognized by Forbes as one of the 10 most powerful businesswomen in Brazil.

"I am excited to join Nuvo’s board of directors at such a pivotal time in the Company's development,”said Adriana Machado. “I look forward to bringing my experience of the international health innovation landscape to help the Company improve access to care for expectant mothers across the globe.”

###

About Nuvo

Nuvo is leading a transformation in pregnancy care by providing clinicians and expectant mothers with access to medically-necessary remote pregnancy monitoring anytime, anywhere. Nuvo’s INVU™ platform is an FDA-cleared remote pregnancy monitoring and management system. It enables the delivery of remote non-stress tests(NSTs) and maternal and fetal heart rate monitoring, while pioneering new data-driven personalized pathways that Nuvo believes can improve future health outcomes. INVU is being used by leading health providers and research institutions across the US and Israel. Nuvo plans to continue to expand the footprint of sales in the US andIsrael and plans to introduce its INVU platform in Europe in 2024, subject to granting of the CE mark it filed in Europe in March 2023, to provide remote access and insights not previously deemed possible. Nuvo is led by a diverse team of experienced business, medical and technology leaders, united in the mission of breaking down barriers to pregnancy care to give every life a better beginning. For more information and complete indications, contraindications, warnings and precautions, and instructions for use, visit www.nuvocares.com.

Forward-LookingStatements

Certain statements contained in this press release may be considered forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of1995, Section 27A of the Securities Act and Section 21E of the Exchange Act.Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,”“likely,” “believe,” “estimate,” “project,” “intend,” and other similar expressions among others. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: (i) the possibility that other anticipated benefits of the business combination will not be realized; (ii)changes in general economic and/or industry specific conditions; (iii) the ability of Nuvo to retain, attract and hire key personnel; (iv) potential adverse reactions or changes to relationships with customers, employees, suppliers or other parties resulting from the completion of the business combination;(v) legislative, regulatory and economic developments; (vi) unpredictability and severity of catastrophic events, including, but not limited to, acts of terrorism, outbreak of war or hostilities and any epidemic, pandemic or disease outbreak (including COVID-19), as well as management’s response to any of the aforementioned factors; and (vii) other risk factors as detailed in the registration statement(File No: 333-274803) on Form F-4 filed by Nuvo with the SEC in connection with the business combination and the prospectus/proxy statement contained therein, as well as those risk factors detailed from time to time in Nuvo’s reports filed with the SEC, including its Annual Report on Form 20-F and other documents filed with the SEC. The foregoing list of important factors is not exhaustive. Except as required by applicable law, Nuvo does not undertake any obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

‍

This article originally appeared on HIT Consultant: https://hitconsultant.net/2024/05/06/femtech-nuvo-goes-public-to-expand-remote-pregnancy-monitoring/

FemTech: Nuvo Goes Public to Expand Remote Pregnancy Monitoring

by Jasmine Pennic 05/06/2024

What You Should Know:

– Nuvo Group D.G. Ltd. (NASDAQ: NUVO) (“Nuvo”), a leader in remote pregnancy monitoring, today announced the successful completion of its business combination with LAMF Global Ventures Corp. I (NASDAQ: LGVC, LGVCU, LGVCW) (“LAMF”), a publicly traded special purpose acquisition company (SPAC).

– As part of the business combination, Nuvo will retain its name and existing management team, trading on the NASDAQ under the ticker symbol “NUVO” starting May 2nd, 2024.

Transforming Pregnancy Care with INVU™

Nuvo’s innovative INVU™ platform addresses health disparities by providing expectant mothers with accessible, high-quality prenatal care. This FDA-cleared system utilizes wearable technology, artificial intelligence (AI), and machine learning to empower both patients and healthcare providers with real-time insights into maternal and fetal health.

Key Features and Benefits of INVU™:

• Physician-prescribed and FDA-cleared
• Enables remote fetal non-stress tests (NSTs) for improved accessibility
• Reduces burdens on healthcare staff
• Provides real-time data for better clinical decision-making
• Utilizes a wearable band and mobile app for data collection
• Streamlines data processing and transmission for clinicians

Business Combination Benefits

This business combination allows Nuvo to tap into capital markets for:

• Expanding commercial operations in the US and Israel
• Fueling international expansion, including European market entry in 2024 (pending CE mark approval)
• Accelerating the development of its innovative pipeline

“Nuvo is committed to solving the inherent problems of a broken pregnancy care system by enabling access to quality care with advanced remote monitoring technology,” said Rice Powell, CEO of Nuvo. "Becoming a public company provides us with the resources to redefine pregnancy care and address health disparities by ensuring that all expectant mothers can receive timely and accurate care, regardless of their background or location.”

This article originally appeared on Femtech Insider: https://femtechinsider.com/nuvo-lamf-global-ventures-public/

Remote Pregnancy Monitoring Company Nuvo Goes Public Through Merger with LAMF Global Ventures

By Femtech Insider Maternal Health, Medical Device, News May 2, 2024

‍

Nuvo Group, a remote pregnancy monitoring company, has reached a significant milestone by finalizing its business combination with LAMF Global Ventures, transitioning into a public company listed on NASDAQ under the ticker symbol NUVO.

At the heart of Nuvo’s platform lies its INVU platform, an FDA-cleared pregnancy monitoring and management system that harnesses wearable technology, AI, and machine learning. INVU empowers both patients and healthcare providers by offering real-time insights into maternal and fetal health, thus bridging geographical gaps and ensuring access to quality care for expectant mothers.

The platform facilitates remote fetal non-stress tests (NSTs) conducted by clinicians, eliminating access barriers, reducing staffing burdens, and providing comprehensive data for informed decision-making. Through a wearable band and mobile app, INVU captures vital maternal and fetal parameters like heart rates and uterine activity signals, which are processed in the cloud and transmitted instantaneously for clinician evaluation.

“Nuvo is committed to solving the inherent problems of a broken pregnancy care system by enabling access to quality care with advanced remote monitoring technology,” said Rice Powell, CEO of Nuvo. “Becoming a public company provides us with the resources to redefine pregnancy care and address health disparities by ensuring that all expectant mothers can receive timely and accurate care, regardless of their background or location.”

The business combination, which was approved at a special meeting of LAMF’s shareholders, held on April 1, 2024 and at an extraordinary general meeting of Nuvo shareholders on March 1, 2024, will enable Nuvo to access capital markets to fuel commercial growth, international expansion, and expedite its innovation pipeline.

Nuvo’s INVU platform, already in use by leading healthcare providers and research institutions in the US and Israel, aims to extend its footprint across Europe in 2024, subject to regulatory approvals.

‍

‍

‍

This was originally published via PRNewswire here.

‍

Remote Pregnancy Care Innovator Nuvo Group Ltd. Becomes Public Company Through Completion of Business Combination with LAMF Global Ventures Corp.

NEWS PROVIDED BY

Nuvo Group Ltd.

May 01, 2024, 16:30 ET

‍

Nuvo Solves Inherent Problems of Access to Quality Pregnancy Care With Advanced FDA-Cleared Pregnancy Monitoring and Management Platform

Company Will Begin Trading on NASDAQ Under Ticker Symbol NUVO as of Thursday May 2, 2024

TEL AVIV, Israel and LOS ANGELES, May 1, 2024 /PRNewswire/ -- Holdco Nuvo Group D.G Ltd (NASDAQ: NUVO) ("Nuvo"), a pioneer in remote pregnancy monitoring, today announced completion of its business combination with LAMF Global Ventures Corp. I (NASDAQ: LGVC) (NASDAQ: LGVCU) (NASDAQ: LGVCW) ("LAMF"), a publicly traded special purpose acquisition company and Nuvo Group Ltd. The combined company will retain the Nuvo name, along with its existing management and operational structure. The company's shares will be listed on NASDAQ under a new ticker symbol (NUVO) as of Thursday, May 2, 2024.

Nuvo is addressing health disparities and breaking down barriers to accessing quality pregnancy care with INVU™️, an advanced pregnancy monitoring and management platform. INVU harnesses wearable technology, AI and machine learning to empower patients and healthcare providers with real-time, actionable insights into maternal-fetal health.

The physician-prescribed, FDA-cleared platform enables clinicians to conduct fetal non-stress tests (NSTs) with patients anywhere, improving accessibility to care, reducing staffing burdens and enhancing the quality and depth of information available for decision-making. The wearable band and mobile app capture maternal and fetal heart rates and uterine activity signals, which are processed in the cloud and transmitted in real-time for clinician interpretation.

The combined company will be led by Nuvo's chief executive officer Rice Powell, a 40-year industry veteran with a proven record for meeting consumer health needs while satisfying payor and provider requirements. Rice is the former CEO and Chairman of the Management Board of Fresenius Medical Care, a dual listed company on the Frankfurt and New York stock exchanges, and a leading global provider of kidney dialysis products and services. He has held several senior leadership positions at Fresenius Medical Care, as well as senior positions at Biogen Inc. and Baxter International Inc. Rice was appointed to Nuvo's Board of Directors in September 2023.

"Nuvo is committed to solving the inherent problems of a broken pregnancy care system by enabling access to quality care with advanced remote monitoring technology," said Rice Powell, CEO of Nuvo. "Becoming a public company provides us with the resources to redefine pregnancy care and address health disparities by ensuring that all expectant mothers can receive timely and accurate care, regardless of their background or location."

The business combination, which was approved at a special meeting of LAMF's shareholders, held on April 1, 2024 and at an extraordinary general meeting of Nuvo shareholders on March 1, 2024, will enable Nuvo to access capital markets to fuel commercial growth, international expansion, and expedite its innovation pipeline.

Nuvo was represented on the business combination by Greenberg Traurig and Meitar, and LAMF was represented by White & Case and Herzog Fox & Neeman.

‍

About Nuvo

Nuvo is leading a transformation in pregnancy care by providing clinicians and expectant mothers with access to medically-necessary remote pregnancy monitoring anytime, anywhere. Nuvo's INVU™ platform is an FDA-cleared remote pregnancy monitoring and management system. It enables the delivery of remote non-stress tests (NSTs) and maternal and fetal heart rate monitoring, while pioneering new data-driven personalized pathways that Nuvo believes can improve future health outcomes. INVU is being used by leading health providers and research institutions across the US and Israel.  Nuvo plans to continue to expand the footprint of sales in the US and Israel and plans to introduce its INVU platform in Europe in 2024, subject to granting of the CE mark it filed in Europe in March 2023, to provide remote access and insights not previously deemed possible. Nuvo is led by a diverse team of experienced business, medical and technology leaders, united in the mission of breaking down barriers to pregnancy care to give every life a better beginning. For more information and complete indications, contraindications, warnings and precautions, and instructions for use, visit www.nuvocares.com.

Forward-Looking Statements

Certain statements contained in this press release may be considered forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act and Section 21E of the Exchange Act, including statements regarding the Business Combination involving LAMF, Nuvo and Holdco, and the ability to consummate the Business Combination. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "anticipate," "plan," "likely," "believe," "estimate," "project," "intend," and other similar expressions among others. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: (i) the possibility that other anticipated benefits of the Business Combination will not be realized, and the anticipated tax treatment of the Business Combination; (ii) the risk that shareholder litigation in connection with the Business Combination or other settlements or investigations may affect the timing or occurrence of the Business Combination or result in significant costs of defense, indemnification and liability; (iii) changes in general economic and/or industry specific conditions; (iv) possible disruptions from the Business Combination that could harm Nuvo's business; (v) the ability of Nuvo to retain, attract and hire key personnel; (ix) potential adverse reactions or changes to relationships with customers, employees, suppliers or other parties resulting from the completion of the Business Combination; (vi) legislative, regulatory and economic developments; (vii) unpredictability and severity of catastrophic events, including, but not limited to, acts of terrorism, outbreak of war or hostilities and any epidemic, pandemic or disease outbreak (including COVID-19), as well as management's response to any of the aforementioned factors; and (viii) other risk factors as detailed in the registration statement (File No: 333-274803) on Form F-4 filed by Holdco with the SEC in connection with the Business Combination and the prospectus/proxy statement contained therein, as well as those risk factors detailed from time to time in Nuvo's reports filed with the SEC, including its Annual Report on Form 20-F and other documents filed with the SEC. The foregoing list of important factors is not exhaustive. Except as required by applicable law, Nuvo does not undertake any obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

No Offer or Solicitation

This press release is for informational purposes only and is neither an offer to purchase, nor a solicitation of an offer to sell, subscribe for or buy any securities or the solicitation of any vote in any jurisdiction pursuant to the Business Combination or otherwise, nor shall there be any sale, issuance or transfer or securities in any jurisdiction in contravention of applicable law. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, or an exemption therefrom, and otherwise in accordance with applicable law.

CONTACTS:

Investor Relations Contact
Nuvo Group
Ryan Kraudel
ryan.kraudel@nuvocares.com

Media Relations Contact
FINN Partners for Nuvo Group
Danny Sudwarts
danny.sudwarts@finnpartners.com
(+1) 469-297-2515

Photo - https://mma.prnewswire.com/media/2402997/Nuvo_Group_Ltd_1.jpg

SOURCE Nuvo Group Ltd.

‍

‍

‍